People: Halozyme Therapeutics Inc (HALO.A)

HALO.A on American Stock Exchange

15.78USD
27 Apr 2015
Change (% chg)

-- (--)
Prev Close
$15.78
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
0
52-wk High
$17.25
52-wk Low
$7.58

Search Stocks

Summary

Name Age Since Current Position

Kathryn Falberg

54 2015 Chairman of the Board

Helen Torley

52 2014 President, Chief Executive Officer, Director

Laurie Stelzer

47 2015 Chief Financial Officer, Senior Vice President

Harry Leonhardt

56 2015 Senior Vice President, Chief Compliance Officer, General Counsel

Athena Countouriotis

42 2015 Senior Vice President, Chief Medical Officer

Jeffrey Henderson

49 2015 Director

Jean-Pierre Bizzari

60 2015 Independent Director

Kenneth Kelley

49 2015 Independent Director

Randal Kirk

61 2007 Independent Director

Connie Matsui

61 2006 Independent Director

Matthew Posard

47 2013 Independent Director

Schond Greenway

Executive Director, Investor Relations & Strategy

Biographies

Name Description

Kathryn Falberg

Ms. Kathryn E. Falberg is Chairman of the Board of Company. She was Independent Director of Halozyme Therapeutics, Inc. Ms. Falberg served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals, PLC from March 2012 to March 2014 after serving as Senior Vice President and Chief Financial Officer since December 2009. From 2001 through 2009, Ms. Falberg worked with a number of smaller companies while serving as a corporate director and audit committee chair for several companies. From 1995 through 2001, Ms. Falberg was with Amgen, Inc., where she served as Senior Vice President, Finance and Strategy and Chief Financial Officer, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer. Ms. Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles and is a Certified Public Accountant, inactive. Ms. Falberg currently serves on the Board and is Chair of the Audit Committee of Medivation, Inc., and aTyr Pharma, Inc.

Helen Torley

Dr. Helen I. Torley is President, Chief Executive Officer, Director of Halozyme Therapeutics, Inc., effective January 6, 2014. Prior to Onyx, Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar® and Stivarga® and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-US markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the US Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P).

Laurie Stelzer

Ms. Laurie Stelzer has been appointed as Chief Financial Officer, Senior Vice President of the Company., effective as of June 15, 2015. Most recently at Shire, Stelzer served as senior vice president of Finance for R&D, Technical Operations and Business Development, and was previously Division CFO for Regenerative Medicine. Before Shire, she spent 15 years at Amgen, in senior leadership roles in finance and business development with responsibilities including the U.S., Canada and International Markets, ultimately serving as the company’s acting treasurer. In this role, she led a leveraged recapitalization that included $10 billion in bond offerings and the corresponding expanded share buyback program, which contributed to an increase in shareholder value. Stelzer earned her B.S. in Accounting from Arizona State University and MBA from the UCLA Anderson School of Management.

Harry Leonhardt

Mr. Harry J. Leonhardt, Esq., is Senior Vice President, Chief Compliance Officer, General Counsel of Halozyme Therapeutics, Inc. Mr. Leonhardt brings more than 30 years of corporate legal, intellectual property, compliance, business development and mergers and acquisitions experience to Halozyme, with an extensive background in the biotechnology sector. He most recently served as senior vice president of Legal and Compliance, and corporate secretary for Amylin Pharmaceuticals, a biotech company acquired by Bristol Myers Squibb in 2012. At Halozyme, he will be responsible for all legal, compliance and intellectual property matters. Prior to joining Amylin, Mr. Leonhardt served as senior vice president, general counsel and corporate secretary for Senomyx; executive vice president of Business Development, general counsel and corporate secretary at Genoptix, Inc.; and senior vice president, general counsel and secretary for Nanogen, Inc. He also held positions of increasing responsibility at Allergan, Inc. including head of worldwide litigation and general counsel for European Operations. Early in his career, Mr. Leonhardt was an attorney at the Los Angeles office of Lyon & Lyon where he represented a number of prominent clients in the biotechnology and pharmaceutical industries. He received his Bachelor of Science degree from the University of the Sciences in Philadelphia and his Juris Doctorate from the University of Southern California Law Center.

Athena Countouriotis

Dr. Athena Countouriotis, M.D., is Senior Vice President, Chief Medical Officer of the Company. During Athena's career, she has participated in or led the clinical development and approvals of three oncology assets (Bosulif®, Sutent®, and Sprycel®). Most recently, Dr. Countouriotis served as Chief Medical Officer at Ambit Biosciences (acquired by Daiichi Sankyo in November 2014) where she was responsible for clinical development, and regulatory affairs. In this capacity, Dr. Countouriotis provided leadership to the development and clinical operations strategies for quizartinib, currently in Phase 3 development for Acute Myeloid Leukemia, and served as a key contributor to the successful initial public offering in May 2013. Prior to her role at Ambit Biosciences, Dr. Countouriotis served as global clinical leader for the Oncology Business Unit of Pfizer Inc. In this role, she led late-stage clinical development and the approvals for Bosulif in Chronic Myelogenous Leukemia (CML). In addition, Athena was a clinical leader for Sutent, participating in a successful U.S. Food and Drug Administration advisory committee meeting leading to the approval of Sutent in pancreatic neuroendocrine tumors. Prior to joining Pfizer, Dr. Countouriotis served as a clinical team director at Bristol-Myers Squibb supporting the development and approvals of Sprycel for the treatment of CML. She began her career at Cell Therapeutics, Inc.

Jeffrey Henderson

Mr. Jeffrey W. Henderson is Director of the Company. Henderson brings nearly 30 years of financial, commercial and pharmaceutical industry expertise to the board, most recently serving for almost 10 years as chief financial officer of $100-billion health care products and services company, Cardinal Health. Henderson served as CFO of Cardinal Health from 2005 until late last year, playing a key role in the company's growth and transformation. During his tenure, the company acquired more than 30 companies, spun-off or sold multi-billion-dollar businesses and expanded into new geographies and market segments. In addition to his financial responsibilities, Henderson also managed commercial operations in China and Canada . Prior to Cardinal Health, Henderson was president and general manager of Eli Lilly Canada Inc. and vice president and corporate controller of Eli Lilly & Co. He joined Lilly in 1998 as vice president and corporate treasurer. His prior experience included 10 years at General Motors Corp., where he served executive and managerial posts in Great Britain , Singapore , New York and Canada . He received his Bachelor of Science degree in electrical engineering from Kettering University , Flint, Mich. and his Master of Business Administration degree from Harvard Graduate School of Business Administration.

Jean-Pierre Bizzari

Dr. Jean-Pierre Bizzari, M.D. is an Independent Director of Company. Dr. Bizzari served as Executive Vice President and Global Head of Oncology of Celgene Corporation since 2012 and as Senior Vice President for Clinical Development Oncology from 2008 to 2012, and oversaw the development and approval of a number of leading oncology products including REVLIMID® (lenalidomide), VIDAZA® (azacitidine), ISTODAX® (romidepsin) and ABRAXANE® (nab-paclitaxel). Prior to 2008, Dr. Bizzari served as Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin® (oxaliplatin), Taxotere® (docetaxel) and Elitek®(rasburicase). Dr. Bizzari was also Vice President, Clinical Development Oncology for Rhône-Poulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of France's National Cancer Institute and is a board member of Transgene. Dr. Bizzari has also been a member of the international scientific committee of the French National Cancer Research Institute since 2005. Jean-Pierre Bizzari is a Doctor of Medicine and a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris. Dr. Bizzari also serves on the board of Celator Pharmaceuticals, Inc.

Kenneth Kelley

Mr. Kenneth J. Kelley, Ph.D., is an Independent Director of Company. Since 2007, Mr. Kelley has served as the Chief Executive Officer of privately held PaxVax, Inc., which is focused on developing innovative vaccines. From April 2002 through June 2004, Mr. Kelley was a General Partner at Latterell Venture Partners, where he made investments in early stage biotechnology and medical device startups. Mr. Kelley founded IntraBiotics Pharmaceuticals in January 1994 and for over eight years served as CEO, Director and Chair of the Board of Directors. Earlier, Mr. Kelley was an Associate at Institutional Venture Partners (IVP), where he participated in the financing of biotech and medical companies. Prior to IVP, he was a consultant for McKinsey & Company and a scientist at Integrated Genetics (acquired by Genzyme). Mr. Kelley earned an M.B.A. from Stanford University and a B.A. in Biochemical Sciences from Harvard University.

Randal Kirk

Mr. Randal J. Kirk is an Independent Director of Halozyme Therapeutics, Inc. Mr. Kirk currently serves as the Senior Managing Director and Chief Executive Officer of Third Security, LLC, an investment management firm founded by Mr. Kirk. Mr. Kirk also currently serves as Chairman of the Board of Directors of Intrexon Corporation since February 2008 and Chief Executive Officer since April 2009. Additionally, Mr. Kirk founded and became Chairman of the Board of New River Pharmaceuticals Inc. (prior to its acquisition by Shire plc in 2007) in 1996, and was President and Chief Executive Officer between October 2001 and April 2007. Mr. Kirk began his professional career in the private practice of law. Previously, Mr. Kirk served as a member of the Board of Directors of Scios, Inc. (prior to its acquisition by Johnson & Johnson) between February 2000 and May 2002, and as a member of the Board of Directors of Clinical Data, Inc. (prior to its acquisition by Forest Laboratories, Inc. in April 2011) from September 2002 to April 2011, and was Chairman of the Board from December 2004 to April 2011. Mr. Kirk currently serves in a number of additional capacities including as a member of the Board of Directors of ZIOPHARM Oncology, Inc. since January 2011. Mr. Kirk served on the Board of Visitors of Radford University from July 2003 to June 2009, was Rector of the Board from September 2006 to September 2008, and served on the Board of Directors of the Radford University Foundation, Inc. from September 1998 to May 2011. He served on the Board of Visitors of the University of Virginia and Affiliated Schools from July 2009 to October 2012, on the Virginia Advisory Council on Revenue Estimates from July 2006 to October 2012 and on the Governor's Economic Development and Jobs Creation Commission from April 2010 to October 2012. Mr. Kirk received a B.A. in Business from Radford University and a J.D. from the University of Virginia.

Connie Matsui

Ms. Connie L. Matsui is an Independent Director of Halozyme Therapeutics, Inc. She retired from Biogen Idec Inc. in January 2009 as the Executive Vice President, Knowledge and Innovation Networks. She served as an Executive Committee member at both Biogen Idec and IDEC Pharmaceuticals, a predecessor of Biogen Idec. Among the major roles she played after joining IDEC Pharmaceuticals in November 1992 were: Senior Vice President, overseeing investor relations, corporate communications, human resources, project management and strategic planning; Collaboration Chair for the late stage development and commercialization of rituximab (tradenames: Rituxan® and MabThera®) in partnership with Roche and Genentech; and Project Leader for Zevalin®, the first radioimmunotherapy approved by the U.S. FDA. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells Fargo Bank in general management, marketing and human resources. Ms. Matsui has been active on a number of not-for-profit boards and served as National President/Board Chair of the Girl Scouts of the USA from 1999 to 2002. Ms. Matsui earned B.A. and M.B.A. degrees from Stanford University.

Matthew Posard

Mr. Matthew L. Posard is an Independent Director of Halozyme Therapeutics, Inc. Mr. Posard is currently Executive Vice President, Chief Commercial Officer of Trovagene, Inc., where he oversees sales, marketing, client services, market and business development. Trovagene is a molecular diagnostic biotechnology company which focuses on precision cancer monitoring. Previously, Mr. Posard was Senior Vice President and General Manager of Illumina, Inc.’s New Emerging Opportunity Business, where he oversaw the development and transfer of Illumina technology into new markets. He joined Illumina in 2006 as Vice President of Global Marketing and served as Vice President of Global Sales from 2007 to 2011, leading Illumina’s successful commercial entry into the life science sequencing market. Prior to joining Illumina, Mr. Posard held various positions in strategic and product marketing at Gen-Probe, Inc., helping the company attain leading market positions in DNA probe-based infectious disease diagnostics and blood banking. Previously, he oversaw global marketing at Biosite, Inc., where he was instrumental in the successful introduction of the company’s BNP congestive heart failure biomarker and its BNP co-marketing collaboration with Beckman Coulter. Mr. Posard holds a B.A. degree in Quantitative Economics and Decision Science from the University of California, San Diego.

Schond Greenway

Search Stocks